SCHEMBL2293229

SCHEMBL2293229

N#Cc1cccc(S(=O)(=O)N2CCC(=NOC(=O)Nc3ccc(F)cc3)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.49
CYP2C9 P11712 1/20 0.44
GAA P10253 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
ATM Q13315 1/20 0.41
AKR1C3 P42330 2/20 0.41
AKR1C1 Q04828 1/20 0.41
PTPN11 Q06124 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292429 0.86 MEN1 (0.50) CYP2C9GAAMEN1KMT2ALMNA
SCHEMBL2294491 0.85 EPHX2 (0.45) CYP2C9GAAMEN1KMT2ALMNA
SCHEMBL2292379 0.84 TSHR (0.50) CYP2C9GAAMEN1KMT2ALMNA
SCHEMBL4380268 0.79 SCN9A (0.47) SCN9ACYP2C9GAAAKR1C3AKR1C1
SCHEMBL2291074 0.76 LMNA (0.53) CYP2C9GAAMEN1KMT2ALMNA
SCHEMBL2294071 0.76 ALDH1A1 (0.51) CYP2C9GAAMEN1KMT2ALMNA
SCHEMBL2292202 0.76 MEN1 (0.50) CYP2C9MEN1KMT2ALMNASMN1; SMN2
SCHEMBL2296034 0.75 KMT2A (0.51) CYP2C9GAAMEN1KMT2ALMNA
SCHEMBL2289836 0.74 EPHX2 (0.47) CYP2C9GAAMEN1KMT2ALMNA
SCHEMBL8225081 0.73 RORC (0.43) SCN9AMEN1KMT2AALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
EP-2164326-A1 AMIDE COMPOUNDS AND THE USE THEREOF Euro-Celtique, S.A. (LU) 2010-03-24 EP disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S SCN9A 67/4885CYP2C9 198/4885GAA 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.